Selected article for: "disease course and limited knowledge"
Author: Christine Dahlke; Jasmin Heidepriem; Robin Kobbe; Rene Santer; Till Koch; Anahita Fathi; My L. Ly; Stefan Schmiedel; Peter H. Seeberger; Marylyn M. Addo; Felix F. Loeffler
Title: Distinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series
  • Document date: 2020_4_17
    • ID: icl1t9d6_31
    Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.14.20059733 doi: medRxiv preprint Discussion SARS-CoV-2 has been rapidly spreading among the human population since the end of 2019. Our knowledge of human immune responses to it is limited and the factors that influence symptoms and severity are largely unknown. To address this, we studied the kinetics of B-cell epitope development in re.....
    Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.14.20059733 doi: medRxiv preprint Discussion SARS-CoV-2 has been rapidly spreading among the human population since the end of 2019. Our knowledge of human immune responses to it is limited and the factors that influence symptoms and severity are largely unknown. To address this, we studied the kinetics of B-cell epitope development in relation to the clinical and immunological features of two patients; one experienced a very mild disease course and the other, a more severe.

    Search related documents:
    Co phrase search for related documents
    • Discussion SARS and human population: 1, 2
    • Discussion SARS and immune response: 1, 2, 3, 4, 5
    • Discussion SARS and severity symptom: 1
    • disease course and human immune response: 1, 2, 3
    • disease course and human population: 1, 2, 3, 4, 5
    • disease course and human population spread: 1
    • disease course and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease course and mild disease course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • disease course and mild disease course experience: 1
    • disease course and severity symptom: 1, 2, 3, 4, 5, 6, 7, 8
    • human immune response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • human immune response knowledge and immune response: 1, 2, 3
    • human population and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • human population and rapidly human population spread: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • human population spread and immune response: 1, 2, 3, 4
    • human population spread and rapidly human population spread: 1, 2, 3, 4, 5, 6, 7, 8
    • immune response and mild disease course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • immune response and rapidly human population spread: 1
    • immune response and severity symptom: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25